Aditxt Inc
For the period ended Dec 31, 2023. Filed Apr 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 16, 2024
ADTX$0.00-8.6%Stored close · as of Jul 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Year Ended · Year Ended | ||||
|---|---|---|---|---|
| December 31, 2023 · December 31, 2022 | ||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||
| Net loss | $(32,390,447) | $(27,649,876) | ||
| Adjustments to reconcile net loss to net cash used in operating activities | ||||
| Stock-based compensation | 1,402,018 | 3,131,368 | ||
| Depreciation expense | 435,027 | 428,977 | ||
| Amortization of intangible assets | 107,556 | 107,000 | ||
| Amortization of debt discount | 2,821,629 | 1,533,048 | ||
| Impairment on notes receivable | - | 543,938 | ||
| Disposal of fixed assets | - | 6,976 | ||
| Gain on note exchange agreement | (51,712) | - | ||
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | 119,635 | (438,117) | ||
| Prepaid expenses | 279,479 | (36,767) | ||
| Deposits | 248,956 | 23,884 | ||
| Inventory | 204,591 | (455,396) | ||
| Accounts payable and accrued expenses | 6,646,457 | 412,959 | ||
| Settlement liability | 1,600,000 | - | ||
| Net cash used in operating activities | (18,576,811) | (22,392,006) | ||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||
| Purchase of fixed assets | (14,407) | (367,079) | ||
| Tenant improvement allowance receivable | - | 125,161 | ||
| Net cash used in investing activities | (14,407) | (241,918) | ||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
| Proceeds from notes - related party | 1,062,523 | 80,000 | ||
| Proceeds from notes and convertible notes payable, net of offering costs | 7,903,445 | 2,795,000 | ||
| Repayments of note payable - related party | (687,523) | (80,000) | ||
| Repayments of note payable | (3,152,488) | (3,206,887) | ||
| Sale of Series B Preferred shares to related party | - | 20,000 | ||
| Redemption of Series B Preferred shares to related party | - | (20,000) | ||
| Common stock and warrants issued for cash, net of issuance costs | 11,054,883 | 17,233,307 | ||
| Sale of Series C Preferred shares to related party | 1,000 | - | ||
| Redemption of Series C Preferred shares to related party | (1,000) | - | ||
| Exercise of warrants, modification of warrants, and issuance of warrants | 1,000 | 1,109,574 | ||
| Payments on financing on fixed asset | (262,160) | (400,491) | ||
| Net cash provided by financing activities | 15,919,680 | 17,530,503 | ||
| NET INCREASE (DECREASE) IN CASH | (2,671,538) | (5,103,421) | ||
| CASH AT BEGINNING OF YEAR | 2,768,640 | 7,872,061 | ||
| CASH AT END OF YEAR | $97,102 | $2,768,640 | ||
| Supplemental cash flow information: | ||||
| Cash paid for income taxes | $ | - | $ | - |
| Cash paid for interest expense | $2,726,020 | $753,038 | ||
| Issuance of shares for the settlement of accounts payable | $ | - | $80,000 | |
| Debt discount from warrants issued with convertible note payable | $ | - | $878,622 | |
| Debt discount from shares issued as inducement for note payable | $ | - | $146,522 | |
| Shares issued for debt offering costs | $354,838 | $96,030 | ||
| Warrant modification | $319,871 | $37,677 | ||
| Deferred issuance costs | $ | - | $50,000 | |
| Issuance of shares of Pearsanta Common Stock for IP | $10,000 | $ | - | |
| Assumption of notes payable from Evofem merger agreement | $11,173,750 | $ | - | |
| Series A-1 Preferred shares issued for exchange agreement | $22,277,233 | $ | - | |
| Accrued intertest rolled into notes payable | $701,315 | $ | - | |
| Series B-2 Preferred shares issued in note exchange agreement | $2,686,306 | $ | - | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.